American Society of Hematology

Fig. 8.

$Fig. 8. G-CSF abrogates the effect of PR3. (○) Shows the dose-dependent reduction of CFU-GM in S-phase at 0.3, 1.5, and 7.5 ng/mL PR3 (2%, 10%, and 50% RBL/PR3 CM, respectively) and (•) shows S-phase fraction with the addition of G-CSF 20 ng/mL during a 2-hour incubation before addition of cytosine arabinoside. At 0.3 and 1.5 ng/mL PR3, G-CSF resulted in a statistically reduced effect of PR3 (P < .01). One representative experiment is shown. The number of colonies per dish in the control without cytosine arabinoside was 244 ± 26 (SD) and 159 ± 12 with cytosine arabinoside, respectively.$

G-CSF abrogates the effect of PR3. (○) Shows the dose-dependent reduction of CFU-GM in S-phase at 0.3, 1.5, and 7.5 ng/mL PR3 (2%, 10%, and 50% RBL/PR3 CM, respectively) and (•) shows S-phase fraction with the addition of G-CSF 20 ng/mL during a 2-hour incubation before addition of cytosine arabinoside. At 0.3 and 1.5 ng/mL PR3, G-CSF resulted in a statistically reduced effect of PR3 (P < .01). One representative experiment is shown. The number of colonies per dish in the control without cytosine arabinoside was 244 ± 26 (SD) and 159 ± 12 with cytosine arabinoside, respectively.

This Feature Is Available To Subscribers Only